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http://www.ro-journal.com/content/9/1/255RESEARCH Open AccessSubmandibular gland-sparing radiation therapy
for locally advanced oropharyngeal squamous cell
carcinoma: patterns of failure and xerostomia
outcomes
Michael F Gensheimer1, Jay J Liao1, Adam S Garden2, George E Laramore1 and Upendra Parvathaneni1*Abstract
Background: Saliva from submandibular glands (SMG) is necessary to minimize xerostomia. It is unclear whether
SMG can be safely spared in patients undergoing bilateral neck radiotherapy for locally advanced oropharyngeal
cancer without increasing the risk of marginal recurrence. We evaluated the outcomes of contralateral submandibular
gland (cSMG) sparing intensity-modulated radiation therapy (IMRT).
Methods: All patients with stage III/IV oropharyngeal squamous cell carcinoma treated with bilateral neck IMRT from
2006–2012 at our institution were included. Appropriately selected patients with favorable primary tumor
characteristics and no definite contralateral neck disease were treated with cSMG-sparing IMRT. Patterns of failure and
xerostomia outcomes were retrospectively analyzed.
Results: 114 patients were treated. 89% had stage IV disease and 89% received definitive radiation therapy. 76 patients
(67%) received cSMG sparing IMRT. With a median follow-up of 30 months, there were 10 local, 9 regional, and 10
distant recurrences. 2-year overall survival was 86% and 2-year loco-regional control was 87%. In cSMG spared patients,
the mean cSMG dose was 30.7 Gy. Late grade 2+ xerostomia was significantly reduced in the cSMG spared group
compared to those without SMG sparing (6 months: 23% vs. 72%, 12 months: 6% vs. 41%, 24 months: 3% vs. 36%, all
p < 0.0007). There were no peri-SMG marginal recurrences in the cSMG-spared cohort.
Conclusions: cSMG sparing IMRT did not increase marginal failures in this series of locally advanced oropharyngeal
SCC patients. Xerostomia was significantly reduced in cSMG spared patients.
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Oropharyngeal squamous cell cancer (OSCC) patients
treated with radiotherapy (RT) are often cured of their
disease [1]. However, chronic xerostomia remains a vex-
ing and common clinical problem that impairs the qual-
ity of life of surviving patients. Sparing of salivary glands
is essential to minimize xerostomia [1]. Parotid-sparing
intensity-modulated radiation therapy (IMRT) is a stand-
ard radiotherapy technique for patients with squamous
cancers of the head and neck region [2-6]. However,* Correspondence: upendra@uw.edu
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article, unless otherwise stated.parotid saliva lacks mucins that maintain a patient’s sub-
jective sense of hydration, and preserving the parotids
alone has inconsistently translated to improvements in
xerostomia [7-10]. Randomized studies comparing parotid-
sparing IMRT with non-parotid-sparing techniques re-
ported that despite better salivary flow rates with IMRT,
the improvement in patient-reported xerostomia scores
were modest [2-4]. One study demonstrated that the
advantage of parotid sparing after therapy was <10
points on a 0–100 scale at one year, and regarded this
difference as clinically insignificant [2]. Thus, parotid-
sparing IMRT may be inadequate for maximizing patient-
related xerostomia outcomes.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of unstimulated saliva and account for almost 95% of
salivary flow during a 24-hour period; this saliva is rich
in mucins [7,8,11]. It has been reported that restricting
the mean dose in one SMG to less than 39 Gy improved
salivary flow and correlated with favorable rates of
patient- and observer-rated xerostomia [12,13].
In patients treated with RT for a locally advanced oro-
pharyngeal SCC, it is seldom possible to spare the ipsi-
lateral SMG as it directly abuts the primary tumor and/
or grossly involved lymph nodes that are treated to a
tumoricidal dose of 66–70 Gy. However, it might be pos-
sible to spare the contralateral SMG (cSMG) since the
level 1B nodes that lie anterior to the gland rarely harbor
metastases from OSCC [14-17]. While it may be desir-
able to spare the cSMG, this is technically demanding
due to its anatomical location in close proximity to
levels II and III jugulodigastric nodal regions that are
electively targeted during the treatment of advanced
OSCC [8,14]. A primary OSCC that crosses the midline
can also makes cSMG sparing difficult. Sparing of the
cSMG is further hindered by the gland’s relatively small
size. A treatment planning study of cSMG-sparing IMRT
reported that in order to reduce the mean cSMG dose
from 54 Gy to 40 Gy it was necessary to accept an
under-dosage of target volumes in the vicinity of the
gland to 90% of prescribed dose [18]. Due to these chal-
lenges, there are concerns that cSMG sparing IMRT
could compromise dose to the adjacent target volumes
in levels II and III and/or the primary tumor, leading to
an increased risk of marginal recurrences [8,14].
There are no randomized trials evaluating the clinical
outcomes of cSMG-sparing IMRT. Two small reports
have compared the effectiveness of cSMG-sparing IMRT
with non-SMG sparing IMRT [19,20]. While both
groups found an improvement in xerostomia with cSMG
sparing, the small sample sizes of 26 and 18 cSMG-
spared patients make it difficult to rule out an increased
marginal recurrence rate from cSMG sparing. Moreover,
both series included patients with a variety of primary
tumor sites, which could complicate their interpretation.
Thus, it is unclear whether the cSMG could be spared to
reduce long term xerostomia, without increasing the risk
of a local-regional recurrence in patients with locally ad-
vanced oropharyngeal SCC requiring bilateral neck RT.
In mid-2006, at the University of Washington we com-
menced a policy of cSMG sparing IMRT, in addition to
standard parotid sparing for the treatment of suitable
OSCC patients. We report the outcomes in patients
with locally advanced OSCC treated with bilateral neck
IMRT at our institution. We divided the patients into
cSMG-spared and cSMG-unspared groups in order to
compare the incidence of peri-SMG marginal failures
and xerostomia.Materials and methods
Institutional Review Board approval was obtained for
this retrospective review of patients treated with IMRT
for advanced OSCC.
Inclusion/exclusion criteria
We identified all patients with stage III/IV OSCC treated
with bilateral neck IMRT at our institution between 2006–
2012. Patients treated for recurrent disease or early stage
(stage I/II) disease, and those receiving unilateral treatment
for well-lateralized tumors (e.g. early tonsil primaries) were
excluded to minimize population heterogeneity. Six pa-
tients were excluded for short follow-up of <6 months.
For analysis of cSMG-sparing comparative outcomes,
patients were divided into two groups, defined as fol-
lows: 1) cSMG spared: contralateral level IB nodal level
was not targeted for elective RT and cSMG had an
IMRT planning objective. 2) cSMG unspared: all other
patients. Patients with nodal involvement limited to the
unilateral neck and who had an anatomically favorable
primary tumor were considered for cSMG sparing. Con-
traindications included a primary tumor extending close
to the cSMG due to risk of under-dosing the tumor, or
primary tumor involvement of the contralateral oral cav-
ity, which would place the level IB space at risk.
Staging and surveillance
Patients were staged per standard NCCN guidelines.
PET or MRI scans were used as clinically indicated.
Surveillance was every 3–4 monthly for 2–3 years, with
increasing follow up intervals thereafter. Neck dissections
were reserved for an incomplete response at >3 months or
for progressive disease.
Radiotherapy technique
Unless there was low neck involvement, patients were
treated with “split field” technique with multi-beam static
IMRT to the primary and upper neck matched with a
supraclavicular AP field using Elekta (Stockholm, Sweden)
treatment machines and Pinnacle (Best, Netherlands) plan-
ning system. Nodal levels were defined per RTOG guide-
lines. A simultaneous integrated boost method was
used. In patients with gross disease, the highest risk tar-
get volume (PTV1) was prescribed 70 Gy in 33 frac-
tions; the intermediate and low risk subclinical volumes
(PTV2 and PTV3) received 62.7 and 57 Gy, respect-
ively. Two patients received a concomitant boost regi-
men. Patients treated postoperatively were prescribed
60, 57 and 54 Gy in 30 fractions to PTV1, PTV2, and
PTV3. Regions harboring close or positive margins and/or
extracapsular nodal spread were boosted to 63–66 Gy. In
order to maximize salivary sparing, for PTV3, CTV to
PTV expansion was limited to 2–5 mm. Although we cov-
ered level II adequately, the anterior extent of PTV3
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contours of all cases were prospectively quality assured by
2 clinicians (UP & JJL), prior to dosimetric planning.
PTVs were covered by the 95% isodose line, although
90-95% coverage was accepted for PTV3 to optimize
SMG sparing. SMG dose was pushed as low as possible
without compromising coverage of PTV1 and PTV2.
When possible, bilateral parotid glands were spared to
achieve mean dose <24 Gy. Spinal cord with a 5 mm
margin was limited to <45 Gy.
Patient positioning was verified with weekly MV port
films or kV cone-beam CT. There was increasing
utilization of daily cone-beam CT since its implementa-
tion in 2010.Statistical analysis
Kaplan-Meier overall survival, disease-free survival and
loco-regional control were calculated. Event times for
death/recurrence were calculated from the first day of
RT. For disease-free survival calculations, events were
recurrence and/or death. Viable tumor cells at time of
salvage neck dissection were counted as a regional fail-
ure. Baseline characteristics were compared between
the cSMG-spared and unspared groups using Fisher’sFigure 1 Submandibular gland sparing treatment plan. Treatment
planning image for a T4N2b right oropharyngeal squamous cell
carcinoma involving the lingual and pharyngeal tonsils, sparing the
contralateral submandibular gland (cSMG). cSMG in teal. High-dose
70Gy PTV1 in red colorwash and corresponding 95% isodose line in red,
63Gy PTV2 in yellow colorwash and 95% isodose line in yellow, 57Gy
PTV3 in orange colorwash and 95% isodose line in orange. Spared cSMG
received a mean dose of 33Gy.exact test and Wilcoxon rank sum test. Calculations
were done with the statistical software R, version 3.0.2
(University of Auckland).
We recorded dosimetric parameters to determine tar-
get coverage. V93% (volume of target receiving at least
93% of prescribed dose) and D95% (minimum dose re-
ceived by 95% of target volume) were recorded per
RTOG 1216 [21]. Mean doses to cSMG and both pa-
rotids were recorded.Definition of “peri-cSMG” recurrence
In order to identify recurrences potentially attributable
to SMG sparing, peri-cSMG recurrences were defined as
any regional nodal relapse in levels I/II/III on the side of
the cSMG, or primary tumor recurrence within 2 cm of
the cSMG.Toxicity analysis
Late toxicity was retrospectively scored using the Common
Terminology Criteria for Adverse Events version 4 [22].
Late toxicity was defined as occurring 6 months or more
after the last day of RT. Grades of xerostomia were re-
corded. Factors predictive of late xerostomia were explored
using univariate and multivariate logistic regression.Results
In total, 114 patients were treated. The patient charac-
teristics are listed in Table 1. Seventy-six patients (67%)
had cSMG sparing and 38 had non-cSMG-sparing IMRT.
Eighty-nine percent of patients had stage IV disease.
Eighty-nine percent of patients had definitive RT and 11%
had post-operative adjuvant RT. Median highest prescribed
dose was 70 Gy in 33 fractions (range 60–72 Gy). 89% re-
ceived concurrent systemic therapy, most commonly cis-
platin on a three weekly cycle. Fifteen percent of patients
underwent consolidation neck dissection <6 months fol-
lowing definitive RT.
Median follow-up in surviving patients was 30 months
(range 8–86). Twenty patients have died. Twenty-three
patients developed recurrent disease. Ten patients had
disease recurrence in the primary site, nine in the re-
gional nodes and ten in distant sites. Table 2 lists pat-
terns of failure by treatment group. Two-year overall
survival was 86%, 2-year disease-free survival was 77%,
and 2-year locoregional control was 87% (Figure 2).
Forty-eight patients were tested for HPV status based on
either p16 immunohistochemistry or HPV DNA probe,
and forty-two were positive. Of the sixty-six patients with
unknown HPV/p16 status, thirty-five had fewer than 20
pack-years smoking history, which suggests that their can-
cers were likely to be HPV-associated [23].










Mean 56 56 56
Range 35-80 24-75 24-80
Radiation therapy role





Yes 64 38 102
No 12 0 12
Disease subsite
Tonsil 41 11 52
Base of tongue 32 20 52
Other/multiple 3 7 10
AJCC stage
III 10 2 12
IVA 53 25 78
IVB 13 11 24
T stage
1 14 2 16
2 28 5 33
3 15 13 28
4a 12 11 23
4b 7 7 14
N stage
0 6 2 8
1 11 1 12
2a 11 1 12
2b 39 11 50
2c 3 17 20
3 6 6 12




spared (n = 38)
Local recurrence 7 3
Regional recurrence 5 4
Distant recurrence 4 6
Any recurrence 13 10
Figure 2 Locoregional control in the entire group. Kaplan-
Meier-estimated locoregional control in patients with advanced
oropharyngeal SCC treated with bilateral neck IMRT (n = 114).
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outcomes
Among the 76 patients who received cSMG sparing
treatment, 87% had stage IV disease and 43% had T3/T4
tumors. 54% had tonsil and 42% had tongue base pri-
maries. 86% had definitive RT.
The mean cSMG dose was 30.7 Gy (range 15.6-56.2).
Mean cSMG dose <39 Gy and <50 Gy were achieved in
sixty-two (82%) and seventy-two (95%) patients, respect-
ively. The mean parotid dose on the SMG-spared side
was 22.5 Gy (range 12.8-33.3).
Target PTV dosimetric coverage was not compromised
by cSMG sparing. For PTV3 on the SMG-spared side,
72/76 of patients had V93% within the RTOG 1216 ac-
ceptable range of >/=97% of PD and 68/76 had D95%
within the acceptable range of 95-107% of PD. Median
V93% was 99% and median D95% was 100%.Figure 3 Late grade 2+ xerostomia by treatment group.
Table 3 Prevalence of late xerostomia by treatment group
cSMG spared cSMG not spared
Grade 6 months 12 months 24 months 6 months 12 months 24 months
(n = 62) (n = 54) (n = 40) (n = 32) (n = 27) (n = 22)
0 11 12 16 1 5 5
1 37 39 23 8 11 9
2 12 3 1 21 11 8
3 2 0 0 2 0 0
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and 12 have died. Thirteen patients developed recurrent
disease. Seven patients had disease recurrence in the pri-
mary site, five in the regional nodes and four in distant sites.
Of the seven patients with primary site recurrences, none
recurred within 2 cm of a spared SMG. Of the five patients
with nodal recurrence, four had disease recurrence on
the initial side of disease involvement. Only one patient
had nodal disease recurrence on the side of a spared
SMG, but disease recurred in level IV. Thus, there were
no peri-SMG recurrences attributable to cSMG sparing
IMRT. 2-year Kaplan-Meier overall survival was 88%;
2-year disease-free survival was 79% and 2-year locore-
gional control was 88%.Figure 4 Xerostomia at 6 months as a function of cSMG dose.
Error bars represent 95% confidence interval.cSMG unspared group
In thirty-eight patients, no attempt was made to spare
the cSMG. Compared to the cSMG spared group, these
patients were more likely to have T4 tumors (odds ratio
2.7, p = 0.02) and contralateral neck disease (odds ratio
18.8, p < 0.0001). While mean parotid gland dose was
similar between the cSMG spared and unspared groups
(32.1 vs. 34.4 Gy, p = 0.17), contralateral parotid dose
was lower in the cSMG spared group (mean 22.5 vs.
27.8 Gy, p < 0.0001). We classified cSMG unspared pa-
tients into two groups indicating why the cSMG was not
spared: 1) Twenty-six had no planning objective to spare
the cSMG, due to contralateral neck disease (n = 21) or
large primary tumors extending in close proximity to the
cSMG (n = 5). 2) Twelve patients had elective targeting
of the contralateral level IB nodal level due to significant
extension of primary tumor into the oral tongue.
10/38 patients developed recurrent disease. Three pa-
tients had disease recurrence in the primary site, four
in the regional nodes and six in distant sites. Of the 38
patients, only one had a recurrence near an unspared
cSMG. This patient had a T4bN2c tumor and devel-
oped a contralateral level IIA recurrence centrally
within the high dose volume. There was no planning
objective to spare the cSMG in this case and the mean
cSMG dose was 68 Gy. This patient also had synchron-
ous distant metastases along with multiple sites of re-
gional failure.Xerostomia outcomes
Xerostomia data at 6, 12, and 24 months after comple-
tion of RT were available for 94, 81, and 62 patients, re-
spectively. Late grade 2+ xerostomia was significantly
reduced in the cSMG spared group compared to those
without SMG sparing (6 months: 23% vs. 72%, 12 months:
6% vs. 41%, 24 months: 3% vs. 36%, all p < 0.0007; Figure 3,
Table 3). There was a positive correlation between cSMG
mean dose and incidence of grade 2+ xerostomia at
6 months for the entire cohort of 114 patients (Figure 4).
Because of the potential for confounders such as parotid
gland dose, univariate and multivariate logistic regression
predicting grade 2+ xerostomia at 6 months was performed
(Table 4). Covariates were cSMG dose, contralateral parotid
dose, T4 vs. T1-3 tumors, tongue base vs. other primary
sites, bilateral vs. unilateral nodal disease, concurrent sys-
temic therapy, and age at treatment. On univariate analysis,
cSMG dose, contralateral parotid dose, T4 tumor, and pres-
ence of bilateral nodal disease were all positively correlated
with xerostomia. On multivariate analysis, only cSMG dose
(OR = 1.07 (1.02-1.11) per Gy, p = 0.002) and T4 tumor
(OR = 3.90 (1.10-14.95), p = 0.04) were predictive of xeros-
tomia. Mean bilateral parotid dose was analyzed as well
and was not a significant predictor of xerostomia on uni-
variate analysis (OR 1.03 (0.97-1.09), p = 0.31) or multivari-
ate analysis (OR 0.99 (0.91-1.07), p = 0.75).
Table 4 Predictors of grade 2+ xerostomia at 6 months









1.07 (1.05-1.11) <0.0001 1.07 (1.02-1.11) 0.002
Contralateral
parotid dose (Gy)
1.10 (1.02-1.21) 0.03 0.92 (0.81-1.04) 0.19
T4 tumor 5.63 (2.21-15.31) 0.0004 3.90 (1.10-14.95) 0.04
Bilateral nodal
disease
6.07 (2.26-17.85) 0.0005 2.67 (0.62-12.01) 0.19
Base of tongue
primary
1.94 (0.84-4.55) 0.12 2.30 (0.71-7.95) 0.17
Concurrent
systemic therapy
5.88 (1.01-111.52) 0.10 2.51 (0.33-53.76) 0.44
Age at treatment 1.03 (0.98-1.08) 0.31 1.02 (0.96-1.09) 0.56
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While parotid-sparing IMRT improves salivary flow rates
and is considered the standard technique for treating pa-
tients with locally advanced OSCC, it may be inadequate
for patient-rated xerostomia, which has a significant ad-
verse impact on quality of life [2,4,9,10]. To further di-
minish the negative consequences of xerostomia, in
2006 we began a program to spare the contralateral sub-
mandibular gland (cSMG) in patients with locally ad-
vanced oropharyngeal cancer without contralateral nodal
involvement, and who had an anatomically suitable pri-
mary tumor. In 76 patients treated with cSMG sparing bi-
lateral neck IMRT, we were able to limit the cSMG mean
dose to 30.7 Gy. Xerostomia was significantly lower in the
cSMG spared group compared to the unspared group, in-
dependent of parotid sparing. The magnitude of benefit
from cSMG sparing seen in this study is notable. The
PARSPORT randomized trial is the largest reported study
comparing parotid sparing versus non-salivary sparing ra-
diation therapy in oropharyngeal cancer patients [2]. In
that study, parotid sparing resulted in a 25% absolute re-
duction in RTOG grade 2+ xerostomia at 12 months. By





Univ. of Washington (present report) 76 86% 30.7
Helsinki Univ., Finland [24] 50 49%* 27.8
VU Univ. Med. Ctr., The Netherlands [30] 20 100% 34.1
Univ. of Michigan [13] 17† 100% ~43
Centre Eugene Marquis, France [31] 8 100% 33.8
*Number is from larger series including other disease sites.
†Patients with contralateral SMG dose <50 Gy were extracted from a larger group o
group, 92% had oropharynx cancer.35% reduction in grade 2+ xerostomia at 12 months. This
benefit was durable, with reduction in xerostomia also
seen at the 24 month time point. While these findings
could be influenced by differences in patient characteris-
tics between the cSMG-spared and unspared groups, the
strong influence of cSMG dose on xerostomia persisted
on multivariate analysis.
This is the largest report comparing outcomes from
cSMG-sparing and non-cSMG sparing IMRT. Two
smaller studies have been reported [19,20]. Saarilahti
et al. reported on 18 patients treated with cSMG-sparing
IMRT and compared their outcomes with 18 patients
who did not have SMG sparing. Xerostomia was reduced
in the SMG-spared group and there were no recurrences
detected in the vicinity of the spared SMG. The SMG
spared group had 8 patients with advanced stage OSCC.
This series was subsequently updated with more patients,
but without a comparative group [24]. Wang et al. re-
ported that xerostomia at 6 months post-treatment was
significantly improved among 26 patients treated with
cSMG-sparing IMRT compared to 26 patients who re-
ceived non-cSMG sparing IMRT. However, this difference
did not persist at a longer follow up of 12 and 18 months
[20]. There was one level II nodal failure in each group.
Only five of their cSMG-spared patients had advanced
stage OSCC. With the large sample size of >100 patients
in the present study and the durable improvement seen in
xerostomia, this report adds valuable information on the
outcomes of cSMG-sparing IMRT in oropharynx cancer.
There are concerns that aggressive cSMG sparing
could compromise adequate coverage of target volumes,
with an increased risk of marginal recurrences [8,14].
Consequences of a marginal miss could be disastrous
[25-28]. For example, peri-parotid recurrences have been
observed in patients who had aggressive parotid sparing
[25]. In order to maximize cSMG sparing, we included
the great vessels of the neck (internal carotid and jugular)
but not the region immediately posterior to the gland in
the elective PTV (Figure 1). This represents a modification
from the existing RTOG contouring guidelines [29]. Our
definition of peri-SMG marginal recurrences was expectedoropharynx cancer
MG
)
Disease outcome Late xerostomia
No peri-SMG recurrence 23% grade 2+ at 6 months
No permanent grade 3 +
No peri-SMG recurrence No permanent grade 3+
No peri-SMG nodal recurrence Not reported
No contralateral level I recurrence No grade 3+
No peri-SMG recurrence No grade 3+
f 78 patients (personal communication with Avraham Eisbruch). Of larger
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sulted as a consequence of SMG sparing. The lack of mar-
ginal relapses in the 76 cSMG spared patients with a
median follow up of 26 months is reassuring. Since most
recurrences in OSCC occur within 2–3 years after radi-
ation therapy, the observed disease control rate should be
maintained well over time.
There are other series reporting on the patterns of fail-
ure following cSMG-sparing IMRT for OSCC, although
they did not have a cSMG unspared group to compare
xerostomia outcomes (Table 5). The largest of these in-
cluded 50 stage I-IV OSCC patients treated at Helsinki
University Hospital along with 30 patients with other
primary tumor locations. There were no recurrences in
nodal levels I, II or the “vicinity” of the spared gland
[24]. Other smaller series report similar outcomes
[13,30,31]. Taken together, these experiences with over
150 patients demonstrate that cSMG sparing for oro-
pharynx SCC patients can be achieved without increas-
ing the risk of marginal failures. However, patient
selection is crucial and we caution against sparing the
cSMG when a large and infiltrative primary cancer ex-
tends in close proximity to the cSMG.
A limitation of our study is the retrospective, non-
randomized design. There were known differences between
the cSMG spared and unspared groups; for instance, there
were more T4 tumors (47% vs 25%) in the unspared group.
Although T4 stage was a significant predictor of worse xer-
ostomia (p = 0.04), cSMG dose remained the strongest pre-
dictor (p = 0.002) in the multivariate analysis. We did not
record objective salivary flow measurements or perform
formal quality of life questionnaires. However, the observed
clinical benefits of SMG sparing and the relationship be-
tween SMG dose and function in our series are consistent
with the published literature [12,13,19,20].
Conclusions
For patients with locally advanced OSCC, cSMG sparing
is feasible in the majority of patients and may be safely
attempted on the side of the neck being planned for elect-
ive nodal irradiation to reduce xerostomia and improve
quality of life. The reduction in xerostomia in this series
was large and clinically meaningful. In the absence of a
randomized controlled study these observational data may
be of value to clinicians considering cSMG-sparing IMRT
for OSCC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MG participated in the design of the study, performed data collection and
analysis, and drafted the manuscript along with UP. JL, AG, and GL contributed
to the design of the study and revised the manuscript. UP participated in the
design of the study and drafted the manuscript along with MG. All authors
read and approved the final manuscript.Acknowledgements
We thank Dr. Ramesh Rengan for helpful discussions.
Author details
1Department of Radiation Oncology, University of Washington Medical
Center, Seattle, WA, USA. 2Department of Radiation Oncology, The University
of Texas MD Anderson Cancer Center, Houston, TX, USA.
Received: 19 August 2014 Accepted: 6 November 2014References
1. Parvathaneni U, Laramore GE, Liao JJ: Technical advances and pitfalls in
head and neck radiotherapy. J Oncol 2012, 2012:597467.
2. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles
EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK,
A’Hern RP, Sydenham MA, Emson M, Hall E: Parotid-sparing intensity
modulated versus conventional radiotherapy in head and neck cancer
(PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet
Oncol 2011, 12:127–136.
3. Pow EHN, Kwong DLW, McMillan AS, Wong MC, Sham JS, Leung LH, Leung
WK: Xerostomia and quality of life after intensity-modulated radiotherapy
vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma:
initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol
Phys 2006, 66:981–991.
4. Kam MKM, Leung S, Zee B, Chau RM, Suen JJ, Mo F, Lai M, Ho R, Cheung
KY, Yu BK, Chiu SK, Choi PH, Teo PM, Kwan WH, Chan AT: Prospective
randomized study of intensity-modulated radiotherapy on salivary gland
function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol
2007, 25:4873–4879.
5. Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S,
Murthy V, Budrukkar A, Dinshaw K, Prabhash K, Chaturvedi P, D’Cruz A:
Three-dimensional conformal radiotherapy (3D-CRT) versus intensity
modulated radiation therapy (IMRT) in squamous cell carcinoma of the
head and neck: a randomized controlled trial. Radiother Oncol 2012,
104:343–348.
6. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA: Xerostomia
and its predictors following parotid-sparing irradiation of head-and-neck
cancer. Int J Radiat Oncol Biol Phys 2001, 50:695–704.
7. Tabak LA: In defense of the oral cavity: structure, biosynthesis, and
function of salivary mucins. Annu Rev Physiol 1995, 57:547–564.
8. Eisbruch A: Reducing xerostomia by IMRT: what may, and may not, be
achieved. J Clin Oncol 2007, 25:4863–4864.
9. Jellema AP, Slotman BJ, Doornaert P, Leemans CR, Langendijk JA: Impact of
radiation induced xerostomia on quality of life after primary
radiotherapy among patients with head and neck cancer. Int J Radiat
Oncol Biol Phys 2007, 69:751–760.
10. Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A: Grading
xerostomia by physicians or by patients after IMRT of head and neck
cancer. Int J Radiat Oncol Biol Phys 2006, 66:445–453.
11. Lavelle CLB: Applied Physiology of the Mouth. Bristol: John Wright and Sons;
1975:145–180.
12. Murdoch-Kinch CA, Kim HM, Vineberg KA, Ship JA, Eisbruch A: Dose-effect
relationships for the submandibular salivary glands and implications for
their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol
Phys 2008, 722:373–382.
13. Little M, Schipper M, Feng FY, Vineberg K, Cornwall C, Murdoch-Kinch CA,
Eisbruch A: Reducing xerostomia after chemo-IMRT for head-and-neck
cancer: beyond sparing the parotid glands. Int J Radiat Oncol Biol Phys
2012, 83:1007–1014.
14. Mendenhall WM, Mendenhall CM, Mendenhall NP: Submandibular
gland-sparing intensity-modulated radiotherapy. Am J Clin Oncol.
in press.
15. Sanguinetti G, Califano J, Stafford E, Fox J, Koch W, Tufano R, Sormani MP,
Forastiere A: Defining the risk of involvement for each neck nodal level
in patients with early T-stage node-positive oropharyngeal carcinoma.
Int J Radiat Oncol Biol Phys 2009, 74:1356–1364.
16. Lindberg R: Distribution of cervical lymph node metastases from
squamous cell carcinoma of the upper respiratory and digestive tracts.
Cancer 1972, 29:1446–1449.
Gensheimer et al. Radiation Oncology 2014, 9:255 Page 8 of 8
http://www.ro-journal.com/content/9/1/25517. Jang JW, Parambi RJ, Liliana LS, Liebsch NJ, Chan AW: Intensity modulated
radiation therapy and level 1B nodal coverage for oropharyngeal
carcinoma. Int J Radiat Oncol Biol Phys 2012, 84:S22–S23.
18. Houweling AC, Dijkema T, Roesink JM, Terhaard CH, Raaijmakers CP: Sparing
the contralateral submandibular gland in oropharyngeal cancer patients:
a planning study. Radiother Oncol 2008, 89:64–70.
19. Saarilahti K, Kouri M, Collan J, Kangasmäki A, Atula T, Joensuu H, Tenhunen
M: Sparing of the submandibular glands by intensity modulated
radiotherapy in the treatment of head and neck cancer. Radiother Oncol
2006, 78:270–275.
20. Wang Z-H, Yan C, Zhang Z-Y, Zhang CP, Hu HS, Tu WY, Kirwan J, Mendenhall
WM: Impact of salivary gland dosimetry on post-IMRT recovery of saliva
output and xerostomia grade for head-and-neck cancer patients treated
with or without contralateral submandibular gland sparing: a longitudinal
study. Int J Radiat Oncol Biol Phys 2011, 81:1479–1487.
21. RTOG 1216: randomized phase II/III trial of surgery and postoperative
radiation delivered with concurrent cisplatin versus docetaxel versus
docetaxel and cetuximab for high-risk squamous cell cancer of the head
and neck. [http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.
aspx?study=1216]
22. National Cancer Institute: Common Terminology Criteria for Adverse
Events Version 4.0. [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_5x7.pdf]
23. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A, Gillison
ML: Improved survival of patients with human papillomavirus-positive
head and neck squamous cell carcinoma in a prospective clinical trial.
J Natl Cancer Inst 2008, 100:261–269.
24. Collan J, Kapanen M, Mäkitie A, Nyman H, Joensuu H, Tenhunen M,
Saarilahti K: Submandibular gland-sparing intensity modulated radiotherapy
in the treatment of head and neck cancer: sites of locoregional relapse and
survival. Acta Oncol 2012, 51:735–742.
25. Cannon DM, Lee NY: Recurrence in region of spared parotid gland after
definitive intensity-modulated radiotherapy for head and neck cancer.
Int J Radiat Oncol Biol Phys 2008, 70:660–665.
26. Eisbruch A, Marsh LH, Dawson LA, Bradford CR, Teknos TN, Chepeha DB,
Worden FP, Urba S, Lin A, Schipper MJ, Wolf GT: Recurrences near base of
skull after IMRT for head-and-neck cancer: implications for target
delineation in high neck and for parotid gland sparing. Int J Radiat Oncol
Biol Phys 2004, 59:28–42.
27. Damast S, Wolden S, Lee N: Marginal recurrences after selective targeting
with intensity-modulated radiotherapy for oral tongue cancer. Head Neck
2012, 34:900–906.
28. Chen AM, Farwell DG, Luu Q, Chen LM, Vijayakumar S, Purdy JA: Marginal
misses after postoperative IMRT for head and neck cancer. Int J Radiat
Oncol Biol Phys 2011, 80:1423–1429.
29. Gregoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, Chao C,
Coche E, Cooper JS, Cosnard G, Eisbruch A, El-Sayed S, Emami B, Grau C,
Hamoir M, Lee N, Maingon P, Muller K, Reychler H: CT-based delineation of
lymph node levels and related CTVs in the node-negative neck:
DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother
Oncol 2003, 69:227–236.
30. Doornaert P, Verbakel WF, Rietveld DH, Slotman BJ, Senan S: Sparing the
contralateral submandibular gland without compromising PTV coverage
by using volumetric modulated arc therapy. Radiat Oncol 2011, 6:74.
31. Chajon E, Lafond C, Louvel G, Castelli J, Williaume D, Henry O, Jégoux F,
Vauléon E, Manens JP, Le Prisé E, de Crevoisier R: Salivary gland-sparing
other than parotid-sparing in definitive head-and-neck intensity-
modulated radiotherapy does not seem to jeopardize local control.
Radiat Oncol 2013, 8:132.
doi:10.1186/s13014-014-0255-x
Cite this article as: Gensheimer et al.: Submandibular gland-sparing
radiation therapy for locally advanced oropharyngeal squamous cell
carcinoma: patterns of failure and xerostomia outcomes. Radiation Oncology
2014 9:255.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
